Just when many people across the UK and Europe had begun to put mpox firmly in the rear-view mirror filed away alongside pandemic-era health anxiety as something that happened, was managed, and moved on the virus has returned with a development that scientists describe as genuinely unprecedented. A new recombinant strain of the monkeypox virus has been identified, combining genetic material from two distinct and previously separate viral lineages. It has already been confirmed in the United Kingdom. It has also been detected in India. And Europe's health surveillance systems are now working at heightened intensity to understand exactly what this means for the continent's population. The short answer, according to current risk assessments, is that the threat to the general public remains low but the long answer is considerably more complex, more scientifically significant, and more worthy of your attention than the reassuring headline figure might suggest.
To understand why this new strain matters, you need to understand the landscape of mpox as it existed before this development. When mpox first emerged as a global health concern in 2022, it was through the spread of the clade II strain, which tends to be less deadly than clade I and can spread through sexual contact. However, in late 2024, it was the growing circulation of the deadlier clade I that was causing alarm especially as it appeared to have acquired the ability to spread via sexual transmission, which had not been widely documented in previous clade I outbreaks. (Gavi, the Vaccine Alliance) Clade I has been more deadly, killing up to 10% of people it infects. (Gavi, the Vaccine Alliance) That mortality rate, compared to the far lower figure associated with clade II, is what drove the World Health Organization to declare mpox a public health emergency of international concern in August 2024 the second such declaration the virus had triggered in the space of just three years.
Now, something new has entered the picture. A recombinant strain of the monkeypox virus has been documented, with two cases of this new strain which comprises genomic elements of both clade Ib and clade IIb confirmed in recent months. The first case was detected in the United Kingdom, with a travel history to a country in South-East Asia, and the second was identified in India, with travel history to a country in the Arabian Peninsula. (WHO) Recombination the process by which two related viruses infecting the same individual exchange genetic material to produce a new hybrid virus is a known natural phenomenon. It is not inherently catastrophic. But it is also not something that virologists ever regard as trivial, particularly when the parent strains involved have different transmissibility profiles and different severity patterns. Detailed genome analysis showed that both individuals became ill several weeks apart with the same recombinant strain, suggesting there may be further cases that are currently going undetected. Laboratory confirmation that the strain can replicate and presents potential for onward transmission adds further significance to these findings.
The critical scientific question one that researchers are now actively investigating is what properties this hybrid virus has inherited from each of its parent strains, and whether the combination produces something more transmissible, more clinically severe, or more diagnostically elusive than either clade in isolation. Dr Boghuma Titanji, Assistant Professor of Medicine at Emory University, has warned: "The more mpox circulation we permit, the more opportunities the virus has to recombine and adapt, further entrenching mpox virus as a human pathogen that is not going away." (Gavi, the Vaccine Alliance) That framing mpox as a virus that is actively adapting to human hosts is increasingly the consensus view among virologists who have tracked the pathogen's evolution since the DRC outbreak of 2023.
Meanwhile, even before this recombinant discovery, European countries were already dealing with a steady accumulation of clade Ib cases that were straining the premise of "contained risk." Between 1 February 2026 and 12 March 2026, six cases of clade Ib mpox were reported in Austria, and seven were reported in Sweden, with travel health authorities advising people to "take extra precautions" in both countries. Spain, a destination that receives millions of British tourists every year, confirmed 82 cases of clade Ib mpox in the period leading up to March 2026. Since October 2025, several EU and EEA countries have reported mpox clade I in men who have sex with men with no travel history, suggesting that limited community transmission was already occurring within Europe rather than being exclusively import-driven. (European Centre for Disease Prevention and Control) In the United Kingdom, the first confirmed case of clade Ib was recorded on 30 October 2024, and by 31 January 2026, 25 cases had been reported, the majority with direct or indirect links to travel to countries where clade Ib is actively circulating.
The global backdrop against which all of this is unfolding remains serious. There have been more than 53,000 global cases of clade I mpox linked to the ongoing outbreak in Central and Eastern Africa, and newer outbreaks in several Western European countries are likely related to that ongoing epidemic, with transmission dynamics continuing to evolve. (CDC) The Democratic Republic of the Congo remains the epicentre, but the virus has radiated outward through Uganda, Burundi, Kenya, Madagascar, and beyond and wherever international travel connects those regions to European cities, the potential for importation and limited secondary spread exists. Although the WHO's second public health emergency of international concern declaration for mpox was lifted on 5 September 2025, both clade I and clade II and their subclades continue to circulate globally, leading to substantial outbreaks in African countries, and WHO continues to advise emergency preparedness and response activities.
Understanding mpox symptoms and prevention is no longer niche knowledge reserved for healthcare workers and public health specialists. It is practical information that anyone travelling internationally, or anyone who has multiple sexual partners, needs to have readily available. The mpox symptoms and prevention guidance issued by both the NHS and the European Centre for Disease Prevention and Control (ECDC) is consistent and clear. Human mpox often begins with a combination of fever, headache, chills, exhaustion, lymph node swelling, back pain, and muscle aches, followed by a characteristic rash that typically starts from the site of primary infection and progresses to develop vesicles fluid-filled blisters that can affect any part of the body, including the genitals and mouth. (European Centre for Disease Prevention and Control) After becoming infected with mpox, symptoms usually appear between 5 and 21 days after exposure. People remain contagious until all scabs have fallen off and sores have healed, which can take approximately 10 days to three weeks. (Fit for Travel) One of the particularly difficult features of clade Ib specifically is that, in some cases, lesions are predominantly genital, making the condition harder to recognise and easier to transmit silently before diagnosis is made.
Mpox spreads among humans through direct close physical contact with an infected person, including sexual contact. Transmission can also occur through indirect contact with contaminated materials, through infectious respiratory particles in limited circumstances, and from mother to child through vertical transmission. (WHO) The virus does not require prolonged airborne exposure in the way that some respiratory infections do it is not spreading through public transport carriages or office buildings. But it does spread with uncomfortable ease in settings involving skin-to-skin and sexual contact, and the current European trajectory reflects that reality. The WHO warns that very young children, expectant mothers, and individuals with weakened immune systems particularly those with poorly managed HIV are at heightened risk of severe complications from mpox, which can be life-threatening in these groups. (Surrey Live)
From a travel health perspective, the advice for UK and EU residents has evolved considerably from the more relaxed posture of 2023 and early 2024. Travellers should check for mpox symptoms, including rashes and blisters, before having sex, attending parties, or going to events. They should stay alert for symptoms for up to three weeks after having skin-to-skin or sexual contact with someone new, and should exchange contact details with sexual partners in order to assist contact tracing if a case is subsequently confirmed. (Travelhealthpro) Travellers should also avoid contact with animals in endemic regions particularly rodents and must not eat, cook, or prepare any raw or wild meat from unknown sources while in affected areas. (Travelhealthpro) For those travelling to countries in central or eastern Africa where clade I is circulating, checking the Foreign, Commonwealth and Development Office travel advice and consulting a travel health clinic before departure is strongly advised.
For people who are eligible for vaccination primarily gay, bisexual, and other men who have sex with men, particularly those with multiple partners or who attend venues where sexual contact occurs the mpox vaccine represents a significant layer of protection. Gavi is funding an mpox vaccine stockpile designed to ensure a rapid response to viral outbreaks, which became operational in 2026, while Professor Trudie Lang of the University of Oxford has emphasised that monitoring the evolution of the virus will be critical but increasingly challenging in places with overstretched healthcare resources. (Gavi, the Vaccine Alliance) Within Europe, vaccination programmes have been reinforced in several countries in response to the clade Ib spread, and anyone who believes they may be at elevated risk should speak to their GP or sexual health clinic without delay. Until at least March 2026, Tecovirimat remains the only antiviral drug authorised in the EU for treatment of mpox, and treatment is otherwise primarily supportive managing fever, pain, and preventing secondary bacterial infection. (European Centre for Disease Prevention and Control)
What the recombinant strain discovery does above and beyond its immediate epidemiological significance is change the broader scientific conversation about mpox in a fundamental way. For years, the working assumption was that the two major clades, clade I and clade II, were effectively separate problems with separate transmission networks, separate geographic footprints, and separate clinical trajectories. The detection of a hybrid virus containing genomic elements of both shatters that assumption and introduces a new category of uncertainty. The ECDC has already alerted diagnostic laboratories across the EU and EEA that certain real-time PCR assays used to discriminate between clade I and clade II may produce false negative results for the new clade Ib variant due to a deletion in a key gene region, and laboratories have been advised to ensure they are using validated assays capable of detecting this mutant strain. (European Centre for Disease Prevention and Control) In other words, the tools being used to track the virus across Europe may, in some settings, be returning misleading results which means the true picture of mpox's spread on the continent may be incompletely understood.
WHO's Standing Recommendations on mpox surveillance, laboratory capacity strengthening, risk communication, and vaccine access have been extended through 20 August 2026, and public health authorities are strongly encouraged to ensure access to genomic sequencing capacity for virus clade identification for new cases and clusters.
The ECDC has also noted that wastewater monitoring for the monkeypox virus is not yet systematically carried out across EU member states, with only four of sixteen surveyed countries doing so a gap in passive surveillance that represents a meaningful blind spot in Europe's early warning infrastructure. These are not the signs of a health system that is relaxed about the trajectory of this disease. They are the signs of one that is working hard to stay ahead of a virus that has demonstrated, repeatedly and convincingly, that it does not behave predictably and does not respect the assumptions that were made about it just a few years ago.
Comments
Post a Comment